GILD

GILEAD $GILD TO ACQUIRE ORAL IL-23R INHIBITOR HCXT-2001 FOR $1.27B IN UPFRONT CASH Gilead gains worldwide rights to the IL-23R inhibitor program, including HCXT-2001, an investigational drug being developed for inflammatory bowel disease (IBD). • The deal is expected to reduce GAAP and non-GAAP EPS by $0.79-$0.83 in Q4 2026